Orthofix Medical (OFIX) EBITDA (2010 - 2026)

Orthofix Medical has disclosed EBITDA across 17 years of filings, most recently posting $17.7 million for Q1 2026.

• Quarterly EBITDA rose 134.53% year-over-year to $17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.1 million (up 146.03% YoY) and the FY2025 annual result came in at $118.9 million, up 192.13% from the prior year.
• EBITDA eased to $17.7 million in Q1 2026, from $37.9 million in the prior quarter.
• Over five years, EBITDA peaked at $85.8 million in Q4 2022 and troughed at -$210.5 million in Q4 2023.
• A 5-year average of -$20.3 million and a median of $7.1 million in 2022 frame the typical range for EBITDA.
• Biggest YoY gain for EBITDA was 2444.94% in 2023; the steepest drop was 951.15% in 2023.
• Tracing OFIX's EBITDA over 5 years: stood at $85.8 million in 2022, then tumbled by 345.35% to -$210.5 million in 2023, then gained by 2.47% to -$205.3 million in 2024, then jumped by 118.46% to $37.9 million in 2025, then sank by 53.23% to $17.7 million in 2026.
• Business Quant data shows OFIX's EBITDA at $17.7 million in Q1 2026, $37.9 million in Q4 2025, and $32.5 million in Q3 2025.